



**IIES MCRC**  
VALUE ADDITION  
THROUGH EDUCATION



**PharmaVISION**

# PharmaVISION

*Educating Minds, Empowering Pharma*

**OCTOBER 2025**

**Pharma and Healthcare Insights**

Published by

**PHARMA CLUB**

IES's Management College and Research Centre, Mumbai

# PharmaVISION

## INDIAN PHARMA EXPANDS FOOTPRINT IN RUSSIA WITH LOCALISED PRODUCTION PLANS

Indian pharmaceutical giants are setting their sights on Russia to strengthen bilateral trade and enhance global supply chain integration. Several leading firms are exploring possibilities for localized production, aiming to establish one of the largest API (Active Pharmaceutical Ingredient) hubs in the region. The move aligns with India's goal of increasing drug exports and Russia's pursuit of self-reliance in healthcare manufacturing amid continuing geopolitical shifts.

Companies are considering joint ventures, technology transfers, and infrastructure investments to facilitate smoother regulatory coordination and faster market entry. Industry experts believe this collaboration could open new opportunities for India to solidify its global pharmaceutical leadership while helping Russia secure stable access to essential medicines.



Indian pharmaceutical companies are actively negotiating to establish joint production facilities both in India and across various regions of Russia.

• • • • •

**Expanding pharma collaboration will strengthen trust and trade between India and Russia, deepening their strategic friendship and opening new avenues for joint growth in healthcare and innovation.**

• • • • •

*Source: Times of India*

## RAJASTHAN CHILD'S DEATH LINKED TO COUGH SYRUP NOT PRESCRIBED OR SUPPLIED TO DISTRICT: OFFICIAL



A senior Rajasthan health official clarified that the cough syrup alleged to have caused a child's death in Sikar was neither prescribed by the attending doctor nor supplied to the district's Community Health Centre. Investigation revealed the child and family did not visit the health center on the reported date of syrup consumption. The batch of cough syrup in question is under laboratory testing, with precautionary suspension of its supply across the state.

The state government has formed a committee to assess the findings and any action will follow the test results. Meanwhile, the health ministry emphasized the syrup is not supplied to the affected district under the state's free medicine scheme, and the child's prescription did not include this medication. Authorities continue to monitor the situation closely and have taken precautionary steps to prevent further incidents.

*Source: ET Pharma.com*

## INDIA'S PHARMA POWERHOUSE STAYS STEADY AMID US TARIFF TALKS



India's pharmaceutical industry, a global leader in affordable generics, remains steady despite potential US tariff proposals on branded and patented drugs. The proposed 100% tariff by the US, aimed at boosting domestic manufacturing, has been paused for further discussion, with generics exempted from the tariffs. India's pharma sector, which exports around \$10 billion worth of drugs annually to the US, is largely insulated as generics dominate exports.

Industry experts and the Indian government view this development as manageable, with Indian companies also exploring innovations in biologics and complex drugs, supported by government incentives. This resilience highlights India's critical role in supplying affordable medicines globally while navigating evolving trade dynamics.

*Source: THE ECONOMIC TIMES*

# TOXIC CONTAMINANT DETECTED IN COUGH SYRUP LINKED TO MULTIPLE CHILD DEATHS IN MADHYA PRADESH



Tamil Nadu's State Drug Testing Laboratory detected diethylene glycol (DEG) beyond safe limits in cough syrup samples linked to the deaths of nine children in Madhya Pradesh's Chhindwara district. The syrup, produced by Sresan Pharma, is suspected to have caused kidney failure. Despite earlier negative tests by CDSCO and MP regulators, a multidisciplinary expert team continues investigating.

*Source: ET Pharma.com*



## Cipla to Market Lilly's Tirzepatide under New Brand in India

Cipla has secured rights from Eli Lilly to market the weight-loss and type-2 diabetes drug Tirzepatide under the new brand name 'Yurpeak' in India. The drug will be sold at the same price as Lilly's existing brand, KwikPen, strengthening Cipla's presence in the fast-growing obesity care market.

*Source: The Economic Times*



## Alkermes Expands into Sleep Medicine with \$2.1 Billion Avadel Deal

Alkermes is set to acquire Avadel Pharmaceuticals for up to \$2.1 billion, gaining entry into the sleep medicine market with the approved treatment Lumryz for narcolepsy. The acquisition is expected to close in early 2026.

*Source: PharmExec.com*

# STRATEGIC BUSINESS UPDATES



## AstraZeneca Partners with Algen in \$555 Million Gene Therapy Deal

AstraZeneca has secured an exclusive license deal with US-based Algen Biotechnologies worth up to \$555 million to develop gene therapies using Algen's AI-driven platform. The partnership focuses on therapies targeting immune system-related disorders, with AstraZeneca gaining rights to develop and market approved treatments. This collaboration advances AstraZeneca's goal of enhancing its cell and gene therapy pipeline to boost long-term growth. Algen's proprietary AlgenBrain platform integrates CRISPR gene modulation with AI to decode disease biology and identify novel therapeutic targets.

*Source: Reuters*

## Natco Pharma to Acquire Major Stake in South Africa's Adcock Ingram

Natco Pharma is set to acquire significant stakes in the 135-year-old South African pharmaceutical company Adcock Ingram, in a deal valued at around ₹4.2 billion. The acquisition will make Adcock Ingram a privately-held entity co-owned by Natco and Bidvest, with Natco gaining a strong foothold in the Southern African market. This partnership is expected to help Natco expand its footprint across Africa and enhance access to affordable medicines in the region. Operations at Adcock Ingram will continue normally, with no immediate changes to the product lineup unless economically necessary. The collaboration will leverage Natco's R&D expertise and global marketing reach to drive growth and innovation over time.

*Source: The Hindu Business Line*

# STRATEGIC BUSINESS UPDATES

## Indian Pharma Sector Anticipates Moderate Growth Amid Challenges



India's pharmaceutical sector anticipates moderate growth in the upcoming period, navigating a complex environment marked by pricing pressures, evolving regulatory frameworks, and geopolitical uncertainties. Export demand continues to be a robust driver, supported by India's strong position in generic medicines globally. However, companies are experiencing margin pressures fueled by rising raw material costs and stringent compliance standards.

Additionally, supply chain disruptions and competition in key global markets add to the challenges faced. Despite these hurdles, industry leaders remain optimistic about the sector's long-term prospects, emphasizing innovation, increased investments in R&D, and growing domestic healthcare demand as pivotal growth catalysts. Strategic initiatives to diversify markets and enhance manufacturing capabilities are also underway to sustain and boost future performance.

*Source: Scanxtrade.com*

## Novo Nordisk Shuts Cell Therapy Unit Amid Restructuring



Novo Nordisk has decided to discontinue its cell therapy research and development, laying off nearly 250 employees from the unit as part of a broader restructuring effort. The company is focusing on simplifying its operations, reducing redundancies, and sharpening its core business priorities. Novo Nordisk will seek external manufacturing partners for its innovations while cutting jobs at key sites, including at its major U.S. manufacturing facility.

*Source: Fierce Biotech*



# Did You Know?

Indian companies produce over 60,000 generic versions of drugs, helping reduce healthcare costs globally.

The world's first typhoid vaccine was developed in India in 1896 by Almroth Wright at the Indian Medical Service.

India is actively advancing in biotech, biosimilars, and vaccine manufacturing, becoming a global innovation hub.

India became self-sufficient in producing penicillin during World War II, which was a major breakthrough for the industry.

The Serum Institute of India is the world's largest vaccine manufacturer by volume, producing over 1.5 billion doses annually.

The pharma industry accounts for about 11% of India's total exports and is among the country's top 3 export sectors by value.



## PGDM-Pharmaceutical Management

PGDM Program is a meticulously conceived industry oriented program, approved by AICTE, NBA accredited and Equivalent to MBA by AIU. It is a 2 Year Full Time Program consisting of 6 terms. PGDM-PM is a meticulously conceived industry oriented program, approved by AICTE. It offers a complete insight into the Pharmaceutical sector.

### Editorial Team:

**Anchal Israni**  
anchal.israni24@ies.edu

**Rohit Rane**  
rohit.rane24@ies.edu

**Sanika Narvankar**  
sanika.narvankar24@ies.edu

**Kiran Yadav**  
kiran.yadav24@ies.edu

**Ajay Kharate**  
ajay.kharate24@ies.edu

**Prapti Nagdeve**  
prapti.nagdeve25@ies.edu

**Sunny Roy**  
sunny.roy25@ies.edu

**Janhavi Narvekar**  
janhavi.narvekar25@ies.edu

**Sachi Israni**  
sachi.israni25@ies.edu

**Nishant Choudhari**  
nishant.choudhari25@ies.edu

General Enquiry Address: IES MCRC "Vishwakarma" M.D. Lotlikar Vidya Sankul, 791, S. K. Marg, Bandra Reclamation, Mumbai - 400 050  
 Registrar office / Admin Office no. - 022 - 5000 1725/ 5000 1785  
 For any other enquiry - [ies.mcrc@ies.edu](mailto:ies.mcrc@ies.edu) / [registrar.mcrc@ies.edu](mailto:registrar.mcrc@ies.edu)